{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T07:17:37Z","timestamp":1770880657605,"version":"3.50.1"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Esophageal squamous cell carcinoma (ESCC) is a distinct subtype of esophageal cancer (EC). Research indicates that circadian clock genes (CCGs) in human ESCC are dysregulated. However, the significance of CCGs in ESCC prognosis remains ambiguous. This study sought to establish a complete signature of ESCC-specific differentially expressed CCGs (DE-CCGs) associated with prognosis, tumor growth, and immunological infiltration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Differentially expressed genes (DEGs) between normal and ESCC samples in TCGA database and the GSE23400 dataset were intersected with CCGs to obtain DE-CCGs. The prognosis-related DE-CCGs were discerned to develop a risk model using univariate Cox regression and LASSO regression analyses in TCGA-ESCC. The accuracy of the model was validated using risk and overall survival profiles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seven DE-CCGs (CST3, C1QBP, TTF2, EGFR, CDKN2A, PFAS, TRRAP) were identified in TCGA-ESCC, which were correlated with unfavorable ESCC prognosis. The immune infiltration analysis revealed that High-risk ESCC patients displayed enhanced tumor infiltration. And the combination of CST3 and PD-L1 expression may serve as a potential marker for predicting prognosis of ESCC patients. Moreover, in Vitro experimental models, CST3 expression was markedly elevated in tumor cells and associated with ESCC growth.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This research illustrated the prognostic significance of seven DE-CCGs for ESCC patients based on tumor progression and immune infiltration. And the CST3 may serve as an independent prognostic biomarker and a potential therapeutic target for ESCC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1738892","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T06:51:42Z","timestamp":1770879102000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Construction of circadian clock signature for tumor microenvironment in predicting survival of esophageal squamous cell carcinoma"],"prefix":"10.3389","volume":"17","author":[{"given":"Yiping","family":"Xiang","sequence":"first","affiliation":[{"name":"Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, Tianjin\u2019s Clinical Research Center for Cancer","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuelian","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, Tianjin\u2019s Clinical Research Center for Cancer","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Cui","sequence":"additional","affiliation":[{"name":"Division of Hematology and Transfusion Medicine, Tianjin Medical University Baodi Hospital","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1053\/j.gastro.2022.05.054","article-title":"The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: new estimates from GLOBOCAN 2020","volume":"163","author":"Morgan","year":"2022","journal-title":"Gastroenterology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-321600","article-title":"Global burden of oesophageal and gastric cancer by histology and subsite in 2018","volume":"69","author":"Arnold","year":"2020","journal-title":"Gut"},{"key":"B3","doi-asserted-by":"publisher","first-page":"17048","DOI":"10.1038\/nrdp.2017.48","article-title":"Oesophageal cancer","volume":"3","author":"Smyth","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"B4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41392-020-00323-3","article-title":"Advances in targeted therapy for esophageal cancer","volume":"5","author":"Yang","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.5441","article-title":"Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE-180 study","volume":"5","author":"Shah","year":"2019","journal-title":"JAMA Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"119782","DOI":"10.1016\/j.bbamcr.2024.119782","article-title":"The role of circadian gene CLOCK in cancer","volume":"1871","author":"Rashed","year":"2024","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/ejn.14254","article-title":"Periodicity, repression, and the molecular architecture of the mammalian circadian clock","volume":"51","author":"Rosensweig","year":"2020","journal-title":"Eur J Neurosci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1808","article-title":"Therapeutic targeting of the tumor microenvironment","volume":"11","author":"Bejarano","year":"2021","journal-title":"Cancer Discov"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2021.06.008","article-title":"Circadian regulation of cancer cell and tumor microenvironment crosstalk","volume":"31","author":"Xuan","year":"2021","journal-title":"Trends Cell Biol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.18632\/aging.103509","article-title":"Circadian clock is associated with tumor microenvironment in kidney renal clear cell carcinoma","volume":"12","author":"Zhou","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"100839","DOI":"10.1016\/j.isci.2020.100839","article-title":"A non-canonical function of BMAL1 metabolically limits obesity-promoted triple-negative breast cancer","volume":"23","author":"Ramos","year":"2020","journal-title":"iScience"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00185","article-title":"Expression of the circadian clock gene BMAL1 positively correlates with antitumor immunity and patient survival in metastatic melanoma","volume":"8","author":"de Assis","year":"2018","journal-title":"Front Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1186\/1471-2105-9-559","article-title":"WGCNA: an R package for weighted correlation network analysis","volume":"9","author":"Langfelder","year":"2008","journal-title":"BMC Bioinf"},{"key":"B14","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13148-019-0730-1","article-title":"Statistical predictions with glmnet","volume":"11","author":"Engebretsen","year":"2019","journal-title":"Clin Epigenet"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nature08460","article-title":"Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1","volume":"462","author":"Barbie","year":"2009","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa407","article-title":"TIMER2.0 for analysis of tumor-infiltrating immune cells","volume":"48","author":"Li","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa968","article-title":"CellMiner Cross-Database (CellMinerCDB) version 1.2: Exploration of patient-derived cancer cell line pharmacogenomics","volume":"49","author":"Luna","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/s41419-020-02831-0","article-title":"Y772 phosphorylation of EphA2 is responsible for EphA2-dependent NPC nasopharyngeal carcinoma growth by Shp2\/Erk-1\/2 signaling pathway","volume":"11","author":"Xiang","year":"2020","journal-title":"Cell Death Dis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","article-title":"Dendritic cells in cancer immunology and immunotherapy","volume":"20","author":"Wculek","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00689-z","article-title":"Clinical implications of T cell exhaustion for cancer immunotherapy","volume":"19","author":"Chow","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.852383","article-title":"PI3K\/akt\/mTOR signaling pathway: role in esophageal squamous cell carcinoma, regulatory mechanisms and opportunities for targeted therapy","volume":"12","author":"Luo","year":"2022","journal-title":"Front Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/s41419-022-04941-3","article-title":"Blocking STAT3 signaling augments MEK\/ERK inhibitor efficacy in esophageal squamous cell carcinoma","volume":"13","author":"Zheng","year":"2022","journal-title":"Cell Death Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1330785","article-title":"Perioperative immunotherapy for esophageal squamous cell carcinoma","volume":"15","author":"Wei","year":"2024","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1117523","article-title":"Biomarkers for immunotherapy in esophageal cancer","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12943-018-0790-4","article-title":"Expression, regulation and targeting of receptor tyrosine kinases in esophageal squamous cell carcinoma","volume":"17","author":"Kashyap","year":"2018","journal-title":"Mol Can"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb0738","article-title":"Clocks, cancer, and chronochemotherapy","volume":"371","author":"Sancar","year":"2021","journal-title":"Science"},{"key":"B27","doi-asserted-by":"publisher","first-page":"266","DOI":"10.3390\/biology10040266","article-title":"PER2 circadian oscillation sensitizes esophageal cancer cells to chemotherapy","volume":"10","author":"Redondo","year":"2021","journal-title":"Biol (Basel)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2019.11.009","article-title":"Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy","volume":"470","author":"Lei","year":"2020","journal-title":"Cancer Lett"},{"key":"B29","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/0076-6879(94)44051-4","article-title":"Cystatins","volume":"244","author":"Abrahamson","year":"1994","journal-title":"Methods Enzymol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e18262","DOI":"10.1111\/jcmm.18262","article-title":"Construction of a prognostic model with CAFs for predicting the prognosis and immunotherapeutic response of lung squamous cell carcinoma","volume":"28","author":"Zhang","year":"2024","journal-title":"J Cell Mol Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2020.1739484","article-title":"Cytokines secreted by stromal cells in TNBC microenvironment as potential targets for cancer therapy","volume":"21","author":"Malone","year":"2020","journal-title":"Cancer Biol Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16189","article-title":"LncRNA Snhg1, a non-degradable sponge for miR-338, promotes expression of proto-oncogene CST3 in primary esophageal cancer cells","volume":"8","author":"Yan","year":"2017","journal-title":"Oncotarget"},{"key":"B33","doi-asserted-by":"publisher","first-page":"100347","DOI":"10.1016\/j.xgen.2023.100347","article-title":"Cystatin C is glucocorticoid responsive, directs recruitment of Trem2+ macrophages, and predicts failure of cancer immunotherapy","volume":"3","author":"Kleeman","year":"2023","journal-title":"Cell Genom"},{"key":"B34","doi-asserted-by":"publisher","first-page":"101338","DOI":"10.1016\/j.smim.2019.101338","article-title":"The C1q Receptors: Focus on gC1qR\/p33 (C1qBP, p32, HABP-1)(1)","volume":"45","author":"Ghebrehiwet","year":"2019","journal-title":"Semin Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.1012112","article-title":"C1QBP regulates mitochondrial plasticity to impact tumor progression and antitumor immune response","volume":"13","author":"Wang","year":"2022","journal-title":"Front Physiol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15261","article-title":"Complement C1q binding protein regulates T cells\u2019 mitochondrial fitness to affect their survival, proliferation, and anti-tumor immune function","volume":"113","author":"Tian","year":"2022","journal-title":"Cancer Sci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-023-2538-2","article-title":"Mutual regulation between cell cycle and transcription termination factor TTF2","volume":"68","author":"Hu","year":"2025","journal-title":"Sci China Life Sci"},{"key":"B38","doi-asserted-by":"publisher","first-page":"12828","DOI":"10.3390\/ijms222312828","article-title":"The role of EREG\/EGFR pathway in tumor progression","volume":"22","author":"Cheng","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1236246","article-title":"EGFR alterations in glioblastoma play a role in antitumor immunity regulation","volume":"13","author":"Li","year":"2023","journal-title":"Front Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2016.04.017","article-title":"Implications of genetic and epigenetic alterations of CDKN2A (p16(INK4a)) in cancer","volume":"8","author":"Zhao","year":"2016","journal-title":"EBioMedicine"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e0230306","DOI":"10.1371\/journal.pone.0230306","article-title":"Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations","volume":"15","author":"DeLeon","year":"2020","journal-title":"PloS One"},{"key":"B42","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1053\/j.gastro.2023.05.030","article-title":"Key genetic determinants driving esophageal squamous cell carcinoma initiation and immune evasion","volume":"165","author":"Ko","year":"2023","journal-title":"Gastroenterology"},{"key":"B43","unstructured":""},{"key":"B44","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.molimm.2024.11.002","article-title":"PFAS promotes colorectal cancer progression via regulating RIG-I-mediated innate immune signalling","volume":"176","author":"Ding","year":"2024","journal-title":"Mol Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.69705","article-title":"The TRRAP transcription cofactor represses interferon-stimulated genes in colorectal cancer cells","volume":"11","author":"Detilleux","year":"2022","journal-title":"Elife"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30807","article-title":"Depletion of TRRAP induces p53-independent senescence in liver cancer by down-regulating mitotic genes","volume":"71","author":"Kwan","year":"2020","journal-title":"Hepatology"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.5483\/BMBRep.2018.51.10.042","article-title":"TRRAP stimulates the tumorigenic potential of ovarian cancer stem cells","volume":"51","author":"Kang","year":"2018","journal-title":"BMB Rep"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-024-03313-2","article-title":"USP9X deubiquitinates TRRAP to promote glioblastoma cell proliferation and migration and M2 macrophage polarization","volume":"398","author":"Mu","year":"2025","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241310527","article-title":"Microcystin-LR-induced interaction between M2 tumor-associated macrophage and colorectal cancer cell promotes colorectal cancer cell migration through regulating the expression of TGF-\u03b21 and CST3","volume":"24","author":"Jiang","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B50","doi-asserted-by":"publisher","first-page":"105092","DOI":"10.1016\/j.ebiom.2024.105092","article-title":"A single-cell characterised signature integrating heterogeneity and microenvironment of lung adenocarcinoma for prognostic stratification","volume":"102","author":"Xu","year":"2024","journal-title":"EBioMedicine"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.9846","article-title":"Safety and antitumor activity of the anti-programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma","volume":"36","author":"Doi","year":"2018","journal-title":"J Clin Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02179-2","article-title":"First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial","volume":"29","author":"Song","year":"2023","journal-title":"Nat Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.12836","article-title":"Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial","volume":"326","author":"Luo","year":"2021","journal-title":"Jama"},{"key":"B55","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ccell.2022.02.007","article-title":"Toripalimab plus chemotherapy in treatment-na\u00efve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial","volume":"40","author":"Wang","year":"2022","journal-title":"Cancer Cell"},{"key":"B56","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.cell.2018.09.006","article-title":"A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade","volume":"175","author":"Jerby-Arnon","year":"2018","journal-title":"Cell"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1097667","article-title":"Pan-cancer investigation of C-to-U editing reveals its important role in cancer development and new targets for cancer treatment","volume":"13","author":"Guo","year":"2023","journal-title":"Front Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2020.1829481","article-title":"The potential of cystatin C as a predictive biomarker in breast cancer","volume":"20","author":"Leto","year":"2020","journal-title":"Expert Rev Anticancer Ther"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1738892\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T06:51:44Z","timestamp":1770879104000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1738892\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":58,"alternative-id":["10.3389\/fimmu.2026.1738892"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1738892","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"article-number":"1738892"}}